CPAP and Positive Airway Pressure Therapy for Sleep Apnea

Positive airway pressure (PAP) therapy is the primary evidence-based treatment for obstructive sleep apnea, a condition affecting an estimated 26% of adults between ages 30 and 70 in the United States (American Academy of Sleep Medicine, 2014 prevalence estimate). This page covers the mechanics of CPAP and related PAP modalities, the physiological drivers that make the therapy effective, classification distinctions between device types, tradeoffs in real-world use, and correctives for persistent misconceptions. The scope spans both the clinical structure of PAP therapy and its regulatory and diagnostic context, with the understanding that sleep apnea is a heterogeneous condition requiring individualized assessment through a qualified clinician.

Table of Contents

Definition and scope

Continuous positive airway pressure (CPAP) therapy delivers a steady, prescribed flow of pressurized air through a mask interface to prevent the upper airway from collapsing during sleep. The U.S. Food and Drug Administration (FDA) classifies CPAP devices as Class II medical devices under 21 CFR Part 868, requiring 510(k) clearance before market entry. Broader PAP therapy encompasses not just CPAP but also bilevel, auto-titrating, and adaptive servo-ventilation (ASV) systems — each targeting different apnea phenotypes and patient physiologies.

The diagnostic threshold for treatment is typically set at an Apnea-Hypopnea Index (AHI) of 5 or more events per hour for symptomatic patients, or 15 or more events per hour regardless of symptoms, per criteria outlined by the American Academy of Sleep Medicine (AASM). Medicare coverage for CPAP, governed by CMS Local Coverage Determinations (LCDs), generally requires documented AHI ≥ 15, or AHI ≥ 5 with qualifying comorbidities. The regulatory context for sleep that shapes device coverage and diagnostic standards is a distinct but closely related framework.

Core mechanics or structure

A CPAP machine generates a continuous, positive-pressure airstream — typically set between 4 and 20 centimeters of water pressure (cmH₂O) — through a motor, humidifier chamber, delivery tubing, and a mask. The pressurized airflow acts as a pneumatic splint, maintaining open geometry in the pharyngeal airway throughout inspiration and expiration.

Key hardware components include:

Pressure therapy takes effect by preventing pharyngeal collapse, thereby eliminating obstructive apneas (complete cessation of airflow), hypopneas (partial flow reduction of ≥30% with ≥3% oxygen desaturation or arousal per AASM 2012 updated criteria), and respiratory effort-related arousals (RERAs).

Causal relationships or drivers

The therapeutic mechanism of PAP is directly tied to the anatomical and neuromuscular pathology driving obstructive sleep apnea. During sleep, reduced muscle tone in the genioglossus and other pharyngeal dilators allows soft tissue structures — the tongue base, soft palate, and lateral pharyngeal walls — to approximate or completely obstruct the airway lumen. This produces the repetitive apnea-arousal cycles that fragment sleep architecture and produce hypoxemic episodes.

PAP therapy eliminates the obstruction by maintaining sufficient intraluminal pressure to mechanically prevent tissue collapse. The downstream effects, documented across peer-reviewed literature referenced by both the AASM and the National Heart, Lung, and Blood Institute (NHLBI), include:

Untreated obstructive sleep apnea is associated with increased risk of hypertension, atrial fibrillation, and type 2 diabetes — comorbidities addressed in depth at sleep and cardiovascular health. Effective PAP reduces 24-hour mean arterial blood pressure by approximately 2–3 mmHg in hypertensive patients with OSA, a finding reported in meta-analyses catalogued by the Cochrane Database of Systematic Reviews.

Classification boundaries

PAP therapy is not a single modality. Device classification determines which patients qualify for each type, and conflating them introduces clinical and coverage errors.

CPAP (Continuous PAP): Delivers a single, fixed pressure throughout the entire respiratory cycle. Suitable for straightforward obstructive sleep apnea where a stable titrated pressure resolves events. Pressure is set following an in-lab titration study or via auto-titration data.

APAP (Auto-titrating PAP): Pressure adjusts breath-by-breath within a set range (e.g., 6–16 cmH₂O) based on detected resistance, flow limitation, or snoring signals. APAP is not indicated for central sleep apnea, hypoventilation syndromes, or congestive heart failure.

BiPAP / BPAP (Bilevel PAP): Delivers separate inspiratory (IPAP) and expiratory (EPAP) pressures. Indicated when patients cannot tolerate high CPAP pressures, or when hypoventilation (as in obesity hypoventilation syndrome) requires ventilatory support beyond simple airway splinting.

ASV (Adaptive Servo-Ventilation): Responds dynamically to ventilatory variability, providing servo-controlled pressure support targeting a defined peak flow. The FDA and the American Heart Association issued safety communications after the SERVE-HF trial (published in the New England Journal of Medicine, 2015) found increased cardiovascular mortality with ASV in patients with symptomatic heart failure with reduced ejection fraction (HFrEF) below 45%. ASV is contraindicated in that population per FDA guidance.

CPAP with C-Flex / EPR (Expiratory Pressure Relief): Softens expiratory pressure slightly to improve comfort without fully bifurcating inspiratory and expiratory pressures. These are features within CPAP devices, not separate device classes under FDA.

Tradeoffs and tensions

PAP therapy presents several clinically significant tradeoffs that affect long-term adherence and outcomes.

Efficacy vs. adherence: CPAP achieves near-complete elimination of obstructive events when used correctly, but Medicare defines adequate adherence as use for ≥4 hours per night on ≥70% of nights over a 30-day period. Studies referenced by CMS coverage documentation indicate that 30–50% of patients do not meet this threshold at 12 months.

Pressure comfort vs. event control: Higher pressures better control apneas but increase patient discomfort and may promote central events — a phenomenon called treatment-emergent central sleep apnea (complex sleep apnea syndrome), estimated to occur in approximately 5–15% of OSA patients initiated on PAP therapy (AASM position statement literature).

Auto-titrating flexibility vs. detection accuracy: APAP devices use flow signal algorithms, not direct airway monitoring, and may misclassify artifact or mouth leak as apnea events, driving unnecessary pressure escalation.

Mask interface choices: Nasal pillows carry lower claustrophobia risk but fail when patients breathe through the mouth. Full-face masks address mouth breathing but increase total dead space and are associated with higher rates of skin pressure injury.

Humidification: Heated humidification reduces dryness symptoms but introduces condensate risk in cold bedrooms, and poorly maintained water chambers are a reported source of bacterial contamination if not cleaned per manufacturer schedules.

Common misconceptions

Misconception: CPAP cures sleep apnea permanently.
CPAP is a therapeutic device, not a curative intervention. Obstructive sleep apnea typically returns promptly upon discontinuation of PAP therapy, as the anatomical and neuromuscular factors driving airway collapse persist.

Misconception: Higher pressure is always better.
Therapeutic pressure is a titrated value. Pressure above the minimum effective level increases leak, discomfort, and the risk of treatment-emergent central events without adding clinical benefit.

Misconception: A home sleep test fully characterizes the need for PAP therapy.
Home sleep testing captures respiratory signals but typically excludes EEG-based sleep staging. In-laboratory sleep study polysomnography remains the gold standard for complex presentations, per AASM clinical practice guidelines.

Misconception: APAP is appropriate for all OSA patients.
AASM guidelines specifically exclude APAP use for central sleep apnea, significant comorbid respiratory disease, and congestive heart failure.

Misconception: Mild AHI means PAP therapy is not warranted.
Symptom burden, particularly excessive daytime sleepiness (Epworth Sleepiness Scale scores ≥10) or cardiovascular comorbidity, can make PAP therapy appropriate even when AHI falls in the 5–14 range under CMS LCD criteria.

Checklist or steps (non-advisory)

The following describes the typical process sequence associated with initiating PAP therapy, as structured by standard clinical pathways documented by the AASM and CMS coverage requirements. This is a descriptive process map, not clinical guidance.

  1. Diagnostic testing: Establishment of OSA diagnosis via attended polysomnography or, where appropriate, a home sleep test meeting CMS Type III or Type IV device standards.
  2. AHI and severity documentation: Classification of severity — mild (AHI 5–14), moderate (AHI 15–29), or severe (AHI ≥ 30) — per AASM scoring criteria.
  3. Device type selection: Clinician determination of appropriate PAP modality (CPAP, APAP, BiPAP, or ASV) based on apnea phenotype and comorbidity profile.
  4. Pressure titration: Either in-laboratory attended titration polysomnography or APAP-based home auto-titration to establish therapeutic pressure range.
  5. Mask fitting and interface selection: Selection of nasal pillow, nasal, or full-face interface matched to patient anatomy, breathing pattern, and sleep position.
  6. Initiation and education: Instruction in device operation, mask seal, humidifier use, and cleaning protocols consistent with manufacturer's IFU (Instructions for Use).
  7. 30-day adherence review: Review of device compliance data — hours per night, AHI residual, mask leak rate — to satisfy CMS continued coverage requirements.
  8. Follow-up titration adjustment: Revision of pressure settings or device modality based on adherence data, residual AHI, and patient-reported symptoms.
  9. Ongoing annual review: Periodic reassessment including weight change (which alters OSA severity), equipment replacement eligibility per HCPCS coding schedules, and updated clinical need documentation.

The broader landscape of treatment pathways, including surgical options and oral appliance therapy, is addressed within the sleep disorder diagnosis criteria framework and through referral to a sleep specialist and sleep medicine practice.

Reference table or matrix

PAP Modality Pressure Pattern Primary Indication Key Contraindications FDA Classification
CPAP Single fixed pressure Obstructive sleep apnea (OSA) Central-predominant apnea Class II, 21 CFR §868.5860
APAP Auto-adjusting range OSA without comorbid respiratory disease Central apnea, CHF, COPD, hypoventilation Class II, 21 CFR §868.5860
BiPAP / BPAP Separate IPAP / EPAP OSA with CPAP intolerance; hypoventilation syndromes Requires clinical titration for safe IPAP/EPAP differential Class II
ASV Servo-controlled variable Complex/central sleep apnea; Cheyne-Stokes respiration HFrEF (EF <45%) — FDA safety communication 2015 Class II
BiPAP-ST BPAP with backup rate Hypoventilation, neuromuscular disease Requires specialist titration Class II

Sources: FDA 21 CFR Part 868; AASM Clinical Practice Guidelines; FDA Safety Communication on ASV, 2015.

The sleep statistics united states resource provides population-level data on OSA prevalence and PAP use rates that contextualizes the public health scope of this therapy. The National Sleep Foundation and the American Academy of Sleep Medicine maintain the primary clinical practice guideline infrastructure governing PAP therapy standards in the United States. Additional background on how sleep medicine fits within the broader regulatory and health system framework is available through the site's index of sleep health topics.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)